Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Legal Disputes 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2025 8-K

Show Summary

Show Summary

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

BioCryst Pharmaceuticals disclosed that Annora Pharma submitted an ANDA to the FDA for a generic version of ORLADEYO, challenging three patents that expire in 2039, and the company is suing Annora for patent infringement as of March 10, 2025.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.